Literature DB >> 1760864

D-3-deoxy-3-substituted myo-inositol analogues as inhibitors of cell growth.

G Powis1, I A Aksoy, D C Melder, S Aksoy, H Eichinger, A H Fauq, A P Kozikowski.   

Abstract

A number of unnatural D-3-deoxy-3-substituted myo-inositols were synthesized and their effects on the growth of wild-type NIH 3T3 cells and oncogene-transformed NIH 3T3 cells were studied. The compounds were found to exhibit a diversity of growth-inhibitory activities and showed selectivity in inhibiting the growth of some transformed cells as compared with wild-type cells. Remarkably, D-3-deoxy-3-azido-myo-inositol exhibited potent growth-inhibitory effects toward v-sis-transformed NIH 3T3 cells but had little effect on the growth of wild-type cells. The growth-inhibitory effects of the myo-inositol analogues were antagonized by myo-inositol. Since [3H]-3-deoxy-3-fluoro-myo-inositol was shown to be taken up by cells and incorporated into cellular phospholipids, we suggest that these unnatural myo-inositol analogues may act as antimetabolites in the phosphatidylinositol intracellular signalling pathways. Because cells transformed by oncogenes often exhibit elevated phosphatidylinositol turnover, the inhibition of signalling pathways that mediate oncogene action could offer new opportunities for controlling the growth of cancer cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760864     DOI: 10.1007/bf00687317

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  52 in total

Review 1.  Inositol phosphates: proliferation, metabolism and function.

Authors:  R F Irvine; R M Moor; W K Pollock; P M Smith; K A Wreggett
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1988-07-26       Impact factor: 6.237

2.  A PDGF receptor domain essential for mitogenesis but not for many other responses to PDGF.

Authors:  J A Escobedo; L T Williams
Journal:  Nature       Date:  1988-09-01       Impact factor: 49.962

3.  Invasiveness and chemotactic activity of oncogene transformed NIH/3T3 cells.

Authors:  A Melchiori; S Carlone; G Allavena; O Aresu; S Parodi; S A Aaronson; A Albini
Journal:  Anticancer Res       Date:  1990 Jan-Feb       Impact factor: 2.480

4.  Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains.

Authors:  D Young; G Waitches; C Birchmeier; O Fasano; M Wigler
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

5.  ras-transformed cells: altered levels of phosphatidylinositol-4,5-bisphosphate and catabolites.

Authors:  L F Fleischman; S B Chahwala; L Cantley
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

6.  Activation of phosphatidylinositol 3-kinase by insulin.

Authors:  N B Ruderman; R Kapeller; M F White; L C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  Activated type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) receptor following EGF stimulation.

Authors:  J D Bjorge; T O Chan; M Antczak; H J Kung; D J Fujita
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  The discovery of a 3-phosphomonoesterase that hydrolyzes phosphatidylinositol 3-phosphate in NIH 3T3 cells.

Authors:  D L Lips; P W Majerus
Journal:  J Biol Chem       Date:  1989-11-25       Impact factor: 5.157

9.  Metabolic stability of experimental chemotherapeutic agents in hepatocyte:tumor cell co-cultures.

Authors:  P L Appel; M C Alley; M M Lieber; R Shoemaker; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Autocrine stimulation by the v-sis gene product requires a ligand-receptor interaction at the cell surface.

Authors:  M Hannink; D J Donoghue
Journal:  J Cell Biol       Date:  1988-07       Impact factor: 10.539

View more
  8 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

Review 2.  Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.

Authors:  E J Meuillet
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Cell-signaling targets for antitumour drug development.

Authors:  V G Brunton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen.

Authors:  J Dahl; A Jurczak; L A Cheng; D C Baker; T L Benjamin
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.

Authors:  Lei Du-Cuny; Zuohe Song; Sylvestor Moses; Garth Powis; Eugene A Mash; Emmanuelle J Meuillet; Shuxing Zhang
Journal:  Bioorg Med Chem       Date:  2009-08-19       Impact factor: 3.641

Review 6.  Inhibitors of phosphatidylinositol signalling as antiproliferative agents.

Authors:  G Powis; D Phil
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

7.  Cellular pharmacology of D-3-azido-3-deoxy-myo-inositol, an inhibitor of phosphatidylinositol signaling having antiproliferative activity.

Authors:  G Brunn; A H Fauq; S Chow; A P Kozikowski; A Gallegos; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling.

Authors:  Tania Maffucci; Marco Falasca
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.